Locoregionally-advanced Oropharyngeal Squamous Cell Carcinoma Clinical Trial
Official title:
Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (ROMA LA-OPSCC)
This is a minimal risk feasibility study involving the analysis of patient samples and does not involve any therapeutic intervention. The study will involve a prospective cohort of up to 60 patients diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) treated with chemoradiotherapy (CRT) at Princess Margaret Cancer Centre.
To assess the feasibility of microbiome evaluation in LA-OPSCC patients undergoing CRT using
samples collected by four different methods: Saliva, Oropharyngeal swab over the tumor site
(OP), Stool, and Rectal swab (optional).
This study is investigating the role of oral microbiota as a biomarker in LA-OPSCC. This is a
minimal risk study involving the analysis of patient samples and does not involve therapeutic
intervention. This protocol does not determine eligibility to receive treatment with
concurrent radiotherapy and chemotherapy. It is anticipated that patient accrual will be
completed within 12 months.
The study will involve a prospective cohort of up to 60 patients diagnosed with LA OPSCC
treated with CRT at Princess Margaret Cancer Center.
;